The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Aggressive prostate tumors, including neuroendocrine prostate cancer (NEPC) and prostate adenocarcinoma (PCa) with neuroendocrine lesions, pose significant clinical challenges.
• The ubiquitin ligase Siah2 has emerged as a key regulator in the development of these aggressive cancer subtypes.

Purpose of the Study:

• To review the role of Siah2 in prostate tumor development, focusing on its regulation of hypoxia and neuroendocrine differentiation.
• To highlight the Siah2-HIF-1α/FoxA2 regulatory axis and its implications for novel therapeutic strategies.

Main Methods:

• Review of current scientific literature on Siah2, hypoxia, and prostate cancer.
• Analysis of the molecular mechanisms involving Siah2, HIF-1α, FoxA2, and downstream target genes (Hes6, Sox9, Jmjd1a).

Main Results:

• Siah2 influences the expression and activity of HIF-1α, which then complexes with FoxA2.
• This complex drives the expression of Hes6, Sox9, and Jmjd1a, sufficient for NE tumor and NE lesion formation in PCa.
• These molecular players serve as potential diagnostic and monitoring markers.

Conclusions:

• The Siah2-HIF-1α/FoxA2 pathway is critical for aggressive prostate tumor progression, particularly NEPC.
• Understanding this axis provides a basis for developing targeted therapies against advanced prostate cancer.
• Identifying novel markers can aid in the diagnosis and management of NE lesions and tumors.